Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a Chinese pharmaceutical entity, has announced that it has obtained clinical trial approval from China’s National Medical Products Administration (NMPA) for its biosimilar version of Denmark’s major pharmaceutical company, Novo Nordisk’s semaglutide. Joincare is progressing with the development of this product candidate, aiming to offer an effective therapeutic option for weight management.
The forthcoming clinical trials will evaluate the safety and efficacy of the biosimilar drug in chronic weight management for adult patients. The study will focus on individuals with an initial body mass index (BMI) of 30kg/m² or above, indicating obesity, or 27kg/m² or above, indicating overweight, and who have at least one weight-related comorbidity such as hypertension, dyslipidemia, fatty liver, or obstructive sleep apnea syndrome. Furthermore, Joincare has completed subject recruitment for a Phase III study investigating the drug’s role in type 2 diabetes management.- Flcube.com
